Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina

Circulation

Volumn 96, Issue 4, 1997, Pages 1109-1116

  Cipollone, Francesco ^a   Patrignani, Paola ^a   Greco, Anita ^a   Panara, Maria Rosaria ^a   Padovano, Roberto ^a   Cuccurullo, Franco ^a   Patrono, Carlo ^a   Rebuzzi, Antonio G ^b   Liuzzo, Giovanna ^b   Quaranta, Gaetano ^b   Maseri, Attilio ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Angina; Aspirin; Indobufen; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; INDOBUFEN; PROSTAGLANDIN SYNTHASE; THROMBOXANE;

ADULT; AGED; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; UNSTABLE ANGINA PECTORIS;

EID: 0030795143     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.4.1109     Document Type: Article

References (41)

1. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975;72:2994-2998.
2. 2. Science. 1976;193:1135-1137.
3. Fitzgerald DJ, Roy L, Catella F. FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
4. Thaulow E, Dale J, Kjekshus J, Simonsen S, Hovig T, Solum NO. Pacing induced angina and platelet reactivity. Scand J Clin Lab Invest. 1982;42:607-611.
5. Verbeugt FWA, Serruys PW, Van Vliet H, Spijkers A, Hugenholtz PG. Intracoronary platelet release in patients with and without coronary artery disease. Thromb Haemost. 1983;49:28-31.
6. Nicols AB, Gold KD, Marcella JJ, Canon PJ, Owen J. Effect of pacing-induced myocardial ischemia on platelet activation and fibrin formation in the coronary circulation. J Am Coll Cardiol. 1987;10:40-45.
7. McGill D, McGuiness J, Lloyd J, Ardlie N. Platelet function and exercise induced myocardial ischemia in coronary heart disease patients. Thromb Res. 1989;56:147-158.
8. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981;304:685-691.
9. Hamm CW, Lorenz RL, Bleifeld W, Kupper W, Weber W, Weber PC. Biochemical evidence of platelet activation in patients with unstable angina. J Am Coll Cardiol. 1987;10:988-1004.
10. Vejar M, Fragasso G, Hackett D, Lipkin PD, Maseri A, Born GVR, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost. 1990;63:163-168.
11. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets: acetylation of a particulate protein fraction. J Clin Invest. 1975;56:624-632.
12. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
13. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ II, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688.
14. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filahozzi P, Catella F, Davì G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177-1183.
15. Patrignani P, Volpi D, Ferrario R, Romanzini L, Di Somma M, Patrono C. Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. Eur J Pharmacol. 1990;191:83-88.
16. The SIMBA Group. Indobufen versus aspirin plus dipyridamole after coronary artery bypass surgery. Coron Artery Dis. 1991;2: 897-906.
17. Rajah SM, Rees M, Walker D, Beton D, Ramon A, Dylt J, Powell JD, Drake J. Effects of antiplatelet therapy with indobufen or aspirin-dypyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1994;107: 1146-1153.
18. Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol. 1995;15: 179-194.
19. Karim S, Habib A, Lévy-Toledano S, Maclouf J. Cyclooxygenases-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem. 1996;271:12042-12048.
20. Braunwald E. Unstable angina. Circulation. 1989;80:410-414.
21. Cairns JA, Lewis HD Jr, Meade TW, Sutton GC, Théroux P. Antithrombotic agents in coronary artery disease. Chest. 1995;108: 380S-400S.
22. 2 in man: identification of twenty urinary metabolites. J Biol Chem. 1981;256:8384-8393.
23. 2 in man. Biochim Biophys Acta. 1989; 992:66-70.
24. 2 production in healthy subjects. Thromb Res. 1980; 17:317-327.
25. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, Maclouf J, Patrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705-1712.
26. 2 in human plasma and urine. Biochim Biophys Acta. 1987;918:293-297.
27. Siegel S, Castellan NJ Jr. Nonparametric Statistics for the Behavioral Sciences. 2nd ed. New York, NY: Academic Press Inc; 1986:61-76.
28. 2 production in patients with myocardial infarction. Eur J Clin Pharmacol 1990;39:99-100.
29. Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322: 1769-1774.
30. Davì G, Patrono C, Catalano I, Custro N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. Arterioscler Thromb. 1993;13:1346-1349.
31. Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest. 1989;84:18-27.
32. Ciabattoni G, Ujang S, Sritara P, Andreotti F, Davies G, Simonetti BM, Patrono C, Maseri A. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. J Am Coll Cardiol. 1993;21:1377-1381.
33. Landolfi R, De Candia E, Rocca B, Ciabattoni G, Antinori A, Masetti R, Patrono C. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis 'in vivo.' Thromb Haemost. 1994;72:942-946.
34. Nursing R, Ullrich V. Immunoquantification of thromboxane synthase in human tissues. Eicosanoids. 1990;3:175-180.
35. Lee SH, Soyoola E, Chanmugham P, Hart S, Sun W, Zhong H, Liou S, Simmons D, Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem. 1992;267:25934-25938.
36. O'Sullivan MG, Chilton FH, Huggins EM, McCall CE. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J Biol Chem. 1992;267:14547-14550.
37. O'Sullivan MG, Huggins EM, Meade EA, DeWitt DL, McCall CE. Lipopolysaccharide induces prostaglandin H synthase in alveolar macrophages. Biochem Biophys Res Commun. 1992;187:1123-1127.
38. Maier JAM, Hla T, Maciag T. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem. 1990;265:10805-10808.
39. Habib A, Créminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibody raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem. 1993;268:23448-23454.
40. Tamassia V, Corvi G, Fuccella LM, Moro E, Tosolini G, Tremoli E. Indobufen (K3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man. Eur J Clin Pharmacol. 1979;15:329-333.
41. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989;80:198-205.